<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In over 20 years since the discovery of altered methylation in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, many epigenetic alterations have been found in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, including global and specific gene hypomethylation, hypermethylation, altered chromatin marks, and loss of <z:mp ids='MP_0003121'>genomic imprinting</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> epigenetics has been limited by questions of cause and effect, since epigenetic changes can arise secondary to the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> process and its associated widespread changes in gene expression </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, mutations in the DNA methylation machinery have not been observed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, whereas they have been for chromatin modification </plain></SENT>
<SENT sid="3" pm="."><plain>To address the issue of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> etiology, we have taken a genetic approach to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> epigenetics </plain></SENT>
<SENT sid="4" pm="."><plain>One line of investigation has been on the disorder <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e> (BWS) </plain></SENT>
<SENT sid="5" pm="."><plain>We have found that loss of imprinting (LOI) of the autocrine growth factor gene IGF2 and of the untranslated antisense <z:chebi fb="40" ids="33697">RNA</z:chebi> LIT1, within the K(V)LQT1 gene, account for most cases of BWS, and that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk is specifically associated with LOI of IGF2 </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumors</z:e>, both in BWS and in the general population, involve LOI leading to an expansion of nephrogenic precursor cells </plain></SENT>
<SENT sid="7" pm="."><plain>We have also developed an animal model for the role of LOI of IGF2 in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, showing that it cooperates with Apc mutations to increase <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> frequency, consistent with human data suggesting a severalfold increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk for this common epigenetic variant in the adult population </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that a major component of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk involves epigenetic changes in <z:mpath ids='MPATH_458'>normal</z:mpath> cells that increase the probability of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> after genetic mutation </plain></SENT>
<SENT sid="9" pm="."><plain>They suggest a model of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> prevention that involves the epigenetic analysis of <z:mpath ids='MPATH_458'>normal</z:mpath> cells for risk stratification and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> prevention strategies </plain></SENT>
</text></document>